ICH Q1 stability testing: for anyone working in QA, QC or regulatory affairs, stability studies are one of the pillars of every registration dossier and every pharmaceutical quality system. For more than twenty years, ICH Q1A(R2) has defined the storage conditions, number of batches and minimum data required to assign a shelf life and retest period; today, however, the entire Q1 series is under revision, with a new unified ICH Q1 that reached Step 2 in April 2025 and whose Step 4 adoption is expected in November 2026. In this article we look at what the current rules require, how to set up a compliant study and what to expect from the revision.
ICH stability testing: purpose and Q1A(R2) requirements
The purpose of stability testing is to demonstrate, with experimental data, how the quality of a drug substance or drug product varies over time under the influence of temperature, humidity and light, in order to establish a retest period or shelf life and the labeled storage conditions. ICH Q1A(R2) is the reference text for new drug substances and products, and sets the minimum requirements for registration:
- At least three primary batches for both the drug substance and the drug product; for the product, at least two must be pilot scale, and the third may be smaller if justified.
- At least 12 months of long-term data and 6 months of accelerated data available at submission.
- Testing frequency: every 3 months in the first year, every 6 months in the second, then annually through the proposed shelf life.
- The program is completed with photostability per ICH Q1B and, where applicable, with reduced designs (bracketing and matrixing) per ICH Q1D and statistical evaluation of data per ICH Q1E.
Storage conditions: long term, intermediate and accelerated
The operational core of Q1A(R2) is the table of storage conditions. For the general case, stability chambers must be qualified and monitored at these set points:
| Study | Condition | Minimum data at submission |
|---|---|---|
| Long term (general case) | 25 °C ± 2 °C / 60% RH ± 5% or 30 °C ± 2 °C / 65% RH ± 5% | 12 months |
| Intermediate | 30 °C ± 2 °C / 65% RH ± 5% | 6 months (if triggered by significant change at accelerated) |
| Accelerated | 40 °C ± 2 °C / 75% RH ± 5% | 6 months |
| Refrigerated products — long term | 5 °C ± 3 °C | 12 months |
| Refrigerated products — accelerated | 25 °C ± 2 °C / 60% RH ± 5% | 6 months |
| Frozen products — long term | −20 °C ± 5 °C | 12 months |
For semi-permeable containers (e.g. LDPE bags and bottles), low-humidity conditions apply: long term at 25 °C / 40% RH (or 30 °C / 35% RH) and accelerated at 40 °C with not more than 25% RH, because the dominant risk is water loss rather than moisture uptake.
We cover topics like this every week in The Pragmatic GMP, GuideGxP's free newsletter: updates on ICH, EudraLex and the pharmacopoeias translated into concrete actions for QA and QC. Subscribe so you don't miss the transition to the new ICH Q1.
Significant change: when the accelerated study "fails"
One point inspectors often check is the correct handling of significant change. For the drug product it means: a 5% change in assay from the initial value; any degradation product exceeding its acceptance criterion; failure to meet acceptance criteria for appearance, physical attributes or functionality tests; failure to meet pH or dissolution acceptance criteria. For the drug substance, significant change is any failure to meet specification. If significant change occurs within 6 months at the accelerated condition, the intermediate condition at 30 °C / 65% RH must be initiated, with at least 6 months of data from a 12-month protocol at submission. For semi-permeable containers there is a dedicated criterion: a 5% loss in water after 3 months at 40 °C / ≤25% RH.
The practical consequences are substantial: significant change conditions shelf-life extrapolation (ICH Q1E), the wording of storage statements on the label, and the strength of the rationale with which the QP and regulatory teams defend the retest period in audits and variations.
The new ICH Q1: one guideline instead of six
The most important development to watch today is the revision of the series. The draft of the new ICH Q1 "Stability Testing of Drug Substances and Drug Products", published at Step 2 on April 11, 2025 and put out for public consultation by EMA and FDA until summer 2025, consolidates the current Q1A–Q1F and Q5C into a single document. According to the Expert Working Group's official work plan, Step 3 sign-off and Step 4 adoption are expected in November 2026, with training material planned for 2027. The draft's main changes:
- Extended scope: a single guideline will also cover biological products and vaccines (currently in Q5C) and will include considerations for ATMPs and combination products.
- Risk-based, lifecycle approach: integration of ICH Q8–Q11, Q12 and Q14 principles, with a stability strategy managed across the whole product lifecycle, not just at registration.
- Coverage of all climatic zones, for genuinely global alignment of stability programs.
- New content on in-use stability and reference standards.
Until adoption and regional implementation, the current texts remain binding: the right move now is to map your stability program against the draft and identify gaps, not to unilaterally anticipate requirements that are not yet in force.
GuideGxP recommendation
Three concrete actions to stay audit-ready on stability: (1) verify that protocols and reports correctly cite the conditions, tolerances and significant-change criteria of Q1A(R2), including the dedicated conditions for refrigerated, frozen and semi-permeable presentations; (2) check the qualification and continuous monitoring of your stability chambers, with documented excursion management; (3) start a gap analysis against the new ICH Q1 draft, assigning owners and deadlines ahead of the adoption expected in November 2026.
To work through the ICH Q series in a structured way, the GuideGxP guide Quality Guidelines ICH Q: what is actually applicable, and readiness for the new Q1 analyzes, sentence by sentence, what is truly applicable in the Quality Guidelines and includes a dedicated section on readiness for the new Q1, with ready-to-use operational checklists.
